{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:20:47Z","timestamp":1791429647904,"version":"4.3.3"},"reference-count":144,"publisher":"Elsevier","isbn-type":[{"value":"9780128015834","type":"print"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/bs.irn.2015.07.005","type":"book-chapter","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T03:30:21Z","timestamp":1439868621000},"page":"247-271","source":"Crossref","is-referenced-by-count":65,"title":["Nicotine and Nicotinic Receptor Drugs"],"prefix":"10.1016","author":[{"given":"Maryka","family":"Quik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Bordia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2015.07.005_bb0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11940-011-0117-x","article-title":"Tardive dyskinesia","volume":"13","author":"Aia","year":"2011","journal-title":"Current Treatment Options in Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/14728214.2014.955014","article-title":"Emerging drugs for levodopa-induced dyskinesia","volume":"19","author":"Al Dakheel","year":"2014","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: From structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiological Reviews"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","article-title":"Pathogenesis-targeted, disease-modifying therapies in Parkinson disease","volume":"11","author":"AlDakheel","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.irn.2015.07.005_bb0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/jnnp-2013-306907","article-title":"Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach","volume":"85","author":"Aviles-Olmos","year":"2014","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"16","key":"10.1016\/bs.irn.2015.07.005_bb0035","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1517\/14656560903329102","article-title":"Mecamylamine\u2014A nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders","volume":"10","author":"Bacher","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: Targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2015.07.005_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/jpet.112.194852","article-title":"Varenicline is a potent partial agonist at alpha6beta2* nicotinic acetylcholine receptors in rat and monkey striatum","volume":"342","author":"Bordia","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2015.07.005_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The alpha7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0065","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats","volume":"340","author":"Bordia","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl. 3","key":"10.1016\/bs.irn.2015.07.005_bb0070","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249","author":"Braak","year":"2002","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X","article-title":"Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain","volume":"387","author":"Breese","year":"1997","journal-title":"The Journal of Comparative Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-381328-2.00005-5","article-title":"New approaches to therapy","volume":"98","author":"Brotchie","year":"2011","journal-title":"International Review of Neurobiology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0085","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.108.145292","article-title":"Desensitization of nicotinic acetylcholine receptors as a strategy for drug development","volume":"328","author":"Buccafusco","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pnpbp.2010.10.015","article-title":"Psychopharmacology in autism: An update","volume":"35","author":"Canitano","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends in Neurosciences"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02245195","article-title":"The short-term effect of nicotine chewing gum in patients with Parkinson's disease","volume":"117","author":"Clemens","year":"1995","journal-title":"Psychopharmacology"},{"issue":"16","key":"10.1016\/bs.irn.2015.07.005_bb0105","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"The American Journal of Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/bs.irn.2015.07.005_bb0115","first-page":"113","article-title":"Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism","volume":"16","author":"Dajas","year":"2001","journal-title":"Functional Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/oxfordjournals.aje.a008954","article-title":"Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease","volume":"144","author":"Davis","year":"1996","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.20663","article-title":"Serum uric acid levels and the risk of Parkinson disease","volume":"58","author":"de Lau","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1006\/exnr.1999.7106","article-title":"Nicotine alone and in combination with l-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys","volume":"158","author":"Domino","year":"1999","journal-title":"Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0269881107066855","article-title":"Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)","volume":"21","author":"Dunbar","year":"2007","journal-title":"Journal of Psychopharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2015.07.005_bb0140","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0269881110367727","article-title":"A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment","volume":"25","author":"Dunbar","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"12","key":"10.1016\/bs.irn.2015.07.005_bb0145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0155","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/1531-8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F","article-title":"Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration","volume":"14","author":"Ebersbach","year":"1999","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0160","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/WCO.0b013e3283050461","article-title":"Update in the epidemiology of Parkinson's disease","volume":"21","author":"Elbaz","year":"2008","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: On movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2015.07.005_bb0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-med-092112-142937","article-title":"\u03b17-Nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia","volume":"65","author":"Freedman","year":"2014","journal-title":"Annual Review of Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2015.07.005_bb0175","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.npp.1300975","article-title":"Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia","volume":"31","author":"Gao","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0180","doi-asserted-by":"crossref","first-page":"196028","DOI":"10.1155\/2013\/196028","article-title":"Metabotropic glutamate receptors for Parkinson's disease therapy","volume":"2013","author":"Gasparini","year":"2013","journal-title":"Parkinson's Disease"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/13543784.2012.633510","article-title":"\u03b17 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease","volume":"21","author":"Geerts","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.irn.2015.07.005_bb0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/B978-0-444-52014-2.00042-2","article-title":"Typical and atypical neuroleptics","volume":"100","author":"Gershanik","year":"2011","journal-title":"Handbook of Clinical Neurology"},{"issue":"14","key":"10.1016\/bs.irn.2015.07.005_bb0195","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0024-3205(79)90469-7","article-title":"Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentration","volume":"25","author":"Giorguieff-Chesselet","year":"1979","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0200","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1471-4159.1992.tb08322.x","article-title":"Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum","volume":"59","author":"Grady","year":"1992","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-010-2153-8","article-title":"Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings","volume":"215","author":"Graef","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cne.10659","article-title":"Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta","volume":"461","author":"Han","year":"2003","journal-title":"The Journal of Comparative Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0215","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.21177","article-title":"Smoking-responsive juvenile-onset Parkinsonism","volume":"22","author":"Hanagasi","year":"2007","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0220","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/jnc.12751","article-title":"Dyskinesia in Parkinson's disease: Mechanisms and current non-pharmacological interventions","volume":"130","author":"Heumann","year":"2014","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2015.07.005_bb0225","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1017\/S1461145710001665","article-title":"Acute nicotine enhances strategy-based semantic processing in Parkinson's disease","volume":"14","author":"Holmes","year":"2011","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0230","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0235","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces l-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacological Reviews"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2012.08.012","article-title":"Nicotinic acetylcholine receptors: From basic science to therapeutics","volume":"137","author":"Hurst","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/bs.irn.2015.07.005_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2012.03.023","article-title":"Animal models of l-DOPA-induced dyskinesia: An update on the current options","volume":"211","author":"Iderberg","year":"2012","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2015.07.005_bb0255","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson's disease and l-DOPA induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2015.07.005_bb0260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0022-510X(93)90150-W","article-title":"Effects of smoking in patients with early-onset Parkinson's disease","volume":"117","author":"Ishikawa","year":"1993","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0265","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-8993(88)90092-3","article-title":"Chronic nicotine treatment counteracts the disappearance of tyrosine\u2013hydroxylase\u2013immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection","volume":"455","author":"Janson","year":"1988","journal-title":"Brain Research"},{"issue":"S2","key":"10.1016\/bs.irn.2015.07.005_bb0270","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.21489","article-title":"Functional models of Parkinson's disease: A valuable tool in the development of novel therapies","volume":"64","author":"Jenner","year":"2009","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0306-4522(01)00488-2","article-title":"Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture","volume":"109","author":"Jeyarasasingam","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/bs.irn.2015.07.005_bb0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","article-title":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque","volume":"73","author":"Johnston","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2015.07.005_bb0290","first-page":"274","article-title":"The effects of nicotine on Parkinson's disease","volume":"43","author":"Kelton","year":"2000","journal-title":"Brain and Cognition"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0295","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.parkreldis.2014.01.016","article-title":"Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease","volume":"20","author":"Kobylecki","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2015.07.005_bb0300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-13665-3_6","article-title":"Nicotinic receptors, memory, and hippocampus","volume":"23","author":"Kutlu","year":"2015","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/bs.irn.2015.07.005_bb0305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainresbull.2012.11.003","article-title":"alpha7 nicotinic acetylcholine receptors and their role in cognition","volume":"93","author":"Lendvai","year":"2013","journal-title":"Brain Research Bulletin"},{"issue":"8","key":"10.1016\/bs.irn.2015.07.005_bb0310","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2013.07.021","article-title":"Complex relationships of nicotinic receptor actions and cognitive functions","volume":"86","author":"Levin","year":"2013","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0315","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-319-13665-3_4","article-title":"Heterogeneity across brain regions and neurotransmitter interactions with nicotinic effects on memory function","volume":"23","author":"Levin","year":"2015","journal-title":"Current Topics in Behavioral Neurosciences"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0320","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1046\/j.1471-4159.1998.71062439.x","article-title":"Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors","volume":"71","author":"Maggio","year":"1998","journal-title":"Journal of Neurochemistry"},{"issue":"10","key":"10.1016\/bs.irn.2015.07.005_bb0325","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/BF01273324","article-title":"Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism","volume":"104","author":"Maggio","year":"1997","journal-title":"Journal of Neural Transmission"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00003495-200969050-00003","article-title":"The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism","volume":"69","author":"Malone","year":"2009","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0335","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.29.3.214","article-title":"Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor","volume":"29","author":"Marshall","year":"1966","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0340","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0345","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/exnr.2002.7900","article-title":"Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats","volume":"175","author":"Meshul","year":"2002","journal-title":"Experimental Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0350","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2008.07.041","article-title":"Diversity of vertebrate nicotinic acetylcholine receptors","volume":"56","author":"Millar","year":"2009","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0360","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FBP.0b013e328347546d","article-title":"alpha4beta2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties","volume":"22","author":"Mineur","year":"2011","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0365","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tips.2010.09.004","article-title":"Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis","volume":"31","author":"Mineur","year":"2010","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0370","first-page":"33","article-title":"Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism","volume":"51","author":"Mitsuoka","year":"2002","journal-title":"Hiroshima Journal of Medical Sciences"},{"key":"10.1016\/bs.irn.2015.07.005_bb0375","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0079-6123(10)83010-9","article-title":"Pathophysiological roles for purines: Adenosine, caffeine and urate","volume":"183","author":"Morelli","year":"2010","journal-title":"Progress in Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0380","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuroscience.2006.12.012","article-title":"Acute intermittent nicotine treatment induces fibroblast growth factor-2 in the subventricular zone of the adult rat brain and enhances neuronal precursor cell proliferation","volume":"145","author":"Mudo","year":"2007","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0385","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0390","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm.2165","article-title":"Missing pieces in the Parkinson's disease puzzle","volume":"16","author":"Obeso","year":"2010","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0395","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WCO.0000000000000113","article-title":"Treatment of early Parkinson's disease","volume":"27","author":"Pahwa","year":"2014","journal-title":"Current Opinion in Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0400","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1460-9568.2007.05636.x","article-title":"Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action","volume":"26","author":"Park","year":"2007","journal-title":"The European Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0405","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(25)20464-5","article-title":"An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment","volume":"258","author":"Pauly","year":"1991","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2015.07.005_bb0410","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00415-014-7254-6","article-title":"Deep brain stimulation in Parkinson's disease: Meta-analysis of randomized controlled trials","volume":"261","author":"Perestelo-Perez","year":"2014","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-010-1932-6","article-title":"Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature","volume":"212","author":"Philip","year":"2010","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2015.07.005_bb0420","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4088\/JCP.08m04441","article-title":"Varenicline augmentation in depressed smokers: An 8-week, open-label study","volume":"70","author":"Philip","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.irn.2015.07.005_bb0425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuropharm.2014.12.028","article-title":"Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states","volume":"96","author":"Picciotto","year":"2015","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2015.07.005_bb0430","doi-asserted-by":"crossref","first-page":"e3150","DOI":"10.1371\/journal.pone.0003150","article-title":"Pharmacotherapy of schizophrenic patients: Preponderance of off-label drug use","volume":"3","author":"Pickar","year":"2008","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.irn.2015.07.005_bb0435","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bcp.2009.04.031","article-title":"Nicotinic actions on neuronal networks for cognition: General principles and long-term consequences","volume":"78","author":"Poorthuis","year":"2009","journal-title":"Biochemical Pharmacology"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2015.07.005_bb0440","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.3233\/JAD-2010-091459","article-title":"Effects of caffeine in Parkinson's disease: From neuroprotection to the management of motor and non-motor symptoms","volume":"20","author":"Prediger","year":"2010","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2015.07.005_bb0445","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","article-title":"alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats","volume":"71","author":"Quik","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0450","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: Studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2013","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0460","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0465","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2015.07.005_bb0470","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","article-title":"Nicotine reduces established l-dopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"28","author":"Quik","year":"2013","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2015.07.005_bb0475","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2007.03.001","article-title":"Nicotine neuroprotection against nigrostriatal damage: Importance of the animal model","volume":"28","author":"Quik","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0480","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates","volume":"98","author":"Quik","year":"2006","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0485","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","article-title":"Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice","volume":"63","author":"Quik","year":"2012","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2015.07.005_bb0490","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mds.25028","article-title":"Nicotine as a potential neuroprotective agent for Parkinson's disease","volume":"27","author":"Quik","year":"2012","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0495","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"{alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/bs.irn.2015.07.005_bb0500","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","article-title":"Role for the nicotinic cholinergic system in movement disorders: Therapeutic implications","volume":"144","author":"Quik","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0505","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","article-title":"Role for the nicotinic cholinergic system in movement disorders: Therapeutic implications","volume":"144","author":"Quik","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0510","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1471-4159.1990.tb02341.x","article-title":"Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: Pharmacological characterisation","volume":"54","author":"Rapier","year":"1990","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2015.07.005_bb0515","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2015.07.005_bb0520","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2012.02.031","article-title":"Effects of sazetidine-A, a selective alpha4beta2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats","volume":"682","author":"Rezvani","year":"2012","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0525","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00213-012-2700-6","article-title":"The effects of varenicline on attention and inhibitory control among treatment-seeking smokers","volume":"223","author":"Rhodes","year":"2012","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2015.07.005_bb0530","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0535","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.parkreldis.2014.01.012","article-title":"Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?","volume":"20","author":"Rizzone","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2015.07.005_bb0540","series-title":"The chemical components of tobacco and tobacco smoke","author":"Rodgman","year":"2013"},{"issue":"8","key":"10.1016\/bs.irn.2015.07.005_bb0545","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjp.0703989","article-title":"Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice","volume":"132","author":"Ryan","year":"2001","journal-title":"British Journal of Pharmacology"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2015.07.005_bb0550","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1353-8020(11)70039-6","article-title":"The serotonin system: A potential target for anti-dyskinetic treatments and biomarker discovery","volume":"18","author":"Rylander","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"7","key":"10.1016\/bs.irn.2015.07.005_bb0555","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bcp.2009.04.019","article-title":"nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanisms","volume":"78","author":"Sarter","year":"2009","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0560","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-014-0205-z","article-title":"Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"28","author":"Schaeffer","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0565","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2008.10.005","article-title":"Neurobiology and treatment of Parkinson's disease","volume":"30","author":"Schapira","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0570","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Movement Disorders"},{"issue":"9942","key":"10.1016\/bs.irn.2015.07.005_bb0575","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","article-title":"Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: Future therapeutic perspectives","volume":"384","author":"Schapira","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0580","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.410430308","article-title":"Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment","volume":"43","author":"Schneider","year":"1998","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0585","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0590","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mds.24012","article-title":"Environmental tobacco smoke and Parkinson's disease","volume":"27","author":"Searles Nielsen","year":"2012","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0595","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"4","author":"Seeman","year":"2010","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0600","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Progress in Neurobiology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0605","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0610","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/bpb.32.332","article-title":"Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models","volume":"32","author":"Shimohama","year":"2009","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0615","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/01.wnl.0000196466.99381.5c","article-title":"Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease","volume":"66","author":"Shoulson","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2015.07.005_bb0620","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","article-title":"Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder","volume":"40","author":"Silver","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/bs.irn.2015.07.005_bb0625","first-page":"113","article-title":"Advances in non-dopaminergic treatments for Parkinson's disease","volume":"8","author":"Stayte","year":"2014","journal-title":"Frontiers in Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0630","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-120157","article-title":"The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice","volume":"3","author":"Stuckenholz","year":"2013","journal-title":"Journal of Parkinson's Disease"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2015.07.005_bb0635","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jns.2012.05.029","article-title":"Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia","volume":"319","author":"Suh","year":"2012","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0640","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jnr.23160","article-title":"3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats","volume":"91","author":"Suzuki","year":"2013","journal-title":"Journal of Neuroscience Research"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0645","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/17425255.2011.557066","article-title":"Novel therapy in Parkinson's disease: Adenosine A(2A) receptor antagonists","volume":"7","author":"Szabo","year":"2011","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2015.07.005_bb0650","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/mds.22721","article-title":"Advances in environmental epidemiology","volume":"25","author":"Tanner","year":"2010","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0655","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.58.4.581","article-title":"Smoking and Parkinson's disease in twins","volume":"58","author":"Tanner","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0660","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2015.07.005_bb0665","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0149-7634(02)00008-8","article-title":"The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: Is there a relationship to dopamine D(2) receptor occupancy?","volume":"26","author":"Turrone","year":"2002","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0670","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.57.6.1032","article-title":"Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study","volume":"57","author":"Vieregge","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0675","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1468-1331.2007.01949.x","article-title":"Chronic high dose transdermal nicotine in Parkinson's disease: An open trial","volume":"14","author":"Villafane","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0680","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02244220","article-title":"Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia","volume":"101","author":"Waddington","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2015.07.005_bb0685","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuint.2010.06.005","article-title":"alpha3* and alpha7 nAChR-mediated Ca(2+) transient generation in IMR-32 neuroblastoma cells","volume":"57","author":"Ween","year":"2010","journal-title":"Neurochemistry International"},{"issue":"5","key":"10.1016\/bs.irn.2015.07.005_bb0690","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","article-title":"Plasma urate and risk of Parkinson's disease","volume":"166","author":"Weisskopf","year":"2007","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1016\/bs.irn.2015.07.005_bb0695","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/mds.23695","article-title":"Milestones in research on the pathophysiology of Parkinson's disease","volume":"26","author":"Wichmann","year":"2011","journal-title":"Movement Disorders"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2015.07.005_bb0700","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","article-title":"Epidemiology and etiology of Parkinson's disease: A review of the evidence","volume":"26","author":"Wirdefeldt","year":"2011","journal-title":"European Journal of Epidemiology"},{"issue":"4","key":"10.1016\/bs.irn.2015.07.005_bb0705","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"29","author":"Zhang","year":"2014","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0710","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce l-DOPA-induced dyskinesias in a monkey model of Parkinson's disease","volume":"347","author":"Zhang","year":"2013","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2015.07.005_bb0715","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.114.216283","article-title":"The alpha7 nicotinic receptor agonist ABT-107 decreases l-Dopa-induced dyskinesias in parkinsonian monkeys","volume":"351","author":"Zhang","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.irn.2015.07.005_bb0720","first-page":"141","article-title":"Role of atypical antipsychotics in rapid cycling bipolar disorder: A review of the literature","volume":"23","author":"Zupancic","year":"2011","journal-title":"Annals of Clinical Psychiatry"},{"issue":"8","key":"10.1016\/bs.irn.2015.07.005_bb0725","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bcp.2013.07.032","article-title":"Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics","volume":"86","author":"Zurkovsky","year":"2013","journal-title":"Biochemical Pharmacology"}],"container-title":["International Review of Neurobiology","Nicotine Use in Mental Illness and Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774215000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774215000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:14:03Z","timestamp":1748567643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774215000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9780128015834"],"references-count":144,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2015.07.005","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}